| Literature DB >> 30805021 |
Qiantu Hu1, Huafeng Chen2, Yanli Zuo3, Qin He2, Xuan He2, Steve Simpson4,5, Wei Huang2, Hui Yang2, Haiying Zhang1,6, Rui Lin1,2,6.
Abstract
BACKGROUND: Oil tea is a type of traditional tea beverage used for treating various ailments in minority population in Guangxi, China. Our previous study showed oil tea improved glucose and lipid levels in type 2 diabetic mice. Yet, the underling molecular mechanisms are still not understood. This study aimed at assessing the effect of oil tea on glucose homeostasis and elucidating the molecular mechanisms underlying the oil tea-induced antidiabetic effects.Entities:
Keywords: Fasting blood glucose; Glucose tolerance; Glycolysis/gluconeogenesis pathway; Oil tea; PCK1; RT2 profiler PCR array; SNP; Type 2 diabetes
Year: 2019 PMID: 30805021 PMCID: PMC6373102 DOI: 10.1186/s12986-019-0337-8
Source DB: PubMed Journal: Nutr Metab (Lond) ISSN: 1743-7075 Impact factor: 4.169
Fig. 1Effect of oil tea on blood glucose in db/db mice. a Changes of fasting blood glucose during the 8-week experiment. b The glucose levels of the oral glucose tolerance test (OGTT) at week 4. c The glucose levels of OGTT at week 8. d The AUC levels of OGTT at weeks 4 and 8. FBG, fasting blood glucose; MET, metformin; AUC, area under the curve; control group (n = 7); MET group (n = 10); oil tea group (n = 10). Values are presented as means ± SD. Differences were assessed by one-way ANOVA followed by Newman–Keuls post-hoc tests. *Significantly different from the control group (*p < 0.05, **p < 0.01)
Fig. 2Effect on serum lipid in db/db mice treated with oil tea after 8 weeks. a Effect on TC treated with oil tea. b Effect on TG treated with oil tea. c Effect on LDL treated with oil tea. d Effect on HDL treated with oil tea. e Effect on insulin treated with oil tea. TC, total cholesterol; TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein; MET, metformin; control group (n = 7); MET group (n = 10); oil tea group (n = 10). Values are presented as means ± SD. Differences were assessed by one-way ANOVA followed by Newman–Keuls post-hoc tests. *Significantly different from the control group (*p < 0.05, **p < 0.01)
Fig. 3Weekly body weight of mice. MET, metformin; control group (n = 7); MET group (n = 10); oil tea group (n = 10). Values are presented as means ± SD. Differences were assessed by one-way ANOVA followed by Newman–Keuls post-hoc tests. *Significantly different from the control group (*p < 0.05, **p < 0.01)
Fig. 4Fold changes of the candidate genes expressions between oil tea and control groups by using RT2 profiler PCR array and validated with qPCR. Differences were assessed by t-test or Wilcoxon rank-sum test, as appropriate. *Significantly different from the control group on gene expression (*p < 0.05)
Fig. 5PCK1 expression responded to oil tea treatment. a Decreased hepatic PCK1 expression in oil tea treatment group. b Correlation between PCK1 expression and fasting glucose levels. FBG, fasting blood glucose; control group (n = 7); oil tea group (n = 10). Values are presented as means ± SEM. Differences were assessed by t-test. Correlation analysis was performed with Pearson pairwise test
Fig. 6Pathway and functional ranking summary of PCK1. a Pathway ranking summary of PCK1. b Functional and biological process ranking summary of PCK1. Pathways were annotated according to KEGG, and functional and biological process were annotated by using WebGestalt. Score = −log (false discovery rate, FDR)
The main phenotypic characteristics of the study participants
| Controls ( | T2D Patients ( | ||
|---|---|---|---|
| Sex (male/female) | 89/196 | 45/41 | < 0.001 |
| Age (years) | 53.56 ± 16.33 | 62.62 ± 11.90 | < 0.001 |
| BMI (Kg/m2) | 22.57 ± 3.60 | 23.96 ± 3.24 | 0.003 |
| TG (mmol/L) | 1.45 ± 0.84 | 2.03 ± 1.67 | < 0.001 |
| TC (mmol/L) | 4.69 ± 1.10 | 5.26 ± 1.02 | < 0.001 |
| FBG (mmol/L) | 4.86 ± 0.64 | 8.57 ± 4.02 | < 0.001 |
| HDL-cholesterol (mmol/L) | 1.77 ± 0.46 | 1.72 ± 0.57 | 0.4025 |
| LDL-cholesterol (mmol/L) | 2.27 ± 0.80 | 2.62 ± 0.80 | 0.0004 |
| Anemia ( | 36 (12.9%) | 35 (40.7%) | < 0.001 |
| Family history of diabetes ( | 17 (5.96%) | 3 (3.49%) | 0.373 |
BMI body mass index, TG triglyceride, TC total cholesterol, FBG fasting blood glucose, HDL high density lipoprotein, LDL low density lipoprotein
The association between the rs707555 and rs2071023 in PCK1 and type 2 diabetes, FBG and TG
| Chr/gene | SNP | Allele frequency | Genotype | N | Association with type 2 diabetes | Association with FBG | Association with TG | |||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | * | Coef. (95% CI) | * | Coef. (95%CI) | & | |||||
| chr20/ | rs707555 | C (76.62%) | GG | 215 | ref | ref | ref | |||
| GC | 137 | 0.38 (0.20, 0.71) | 0.002 | −0.67 (−1.20, -0.13) | 0.015 | −0.06 (− 0.28, 0.16) | 0.60 | |||
| G (23.38%) | CC | 18 | 0.18 (0.05, 1.20) | 0.08 | −0.79 (−2.03, 0.44) | 0.21 | −0.39 (− 0.90, 0.11) | 0.12 | ||
| p-trend = 0.001 | p-trend = 0.01 | p-trend = 0.20 | ||||||||
| chr20/ | rs2071023 | C (65.73%) | CC | 153 | ref | ref | ref | |||
| CG | 183 | 1.94 (1.06, 3.58) | 0.03 | 0.51 (−0.03, 1.06) | 0.07 | 0.10(−0.13, 0.32) | 0.40 | |||
| G (34.27%) | GG | 36 | 2.39 (0.92, 6.22) | 0.07 | 0.30 (−0.61, 1.21) | 0.52 | 0.47 (0.10, 0.85) | 0.013 | ||
| p-trend = 0.022 | p-trend = 0.17 | p-trend = 0.027 |
*p-value adjusted for age, sex, BMI, family-history of diabetes, TG and TC
&p-value adjusted for age, sex, BMI and TC
Chr chrome, SNP single nucleotide polymorphism, PCK1 Phosphoenolpyruvate carboxykinase 1, FBG fasting blood glucose, BMI body mass index, TG triglyceride, TC total cholesterol